Double bond in the side chain of 1 alpha,25-dihydroxy-22-ene-vitamin D-3 is reduced during its metabolism: studies in chronic myeloid leukemia (RWLeu-4) cells and rat kidney

Citation
Ds. Rao et al., Double bond in the side chain of 1 alpha,25-dihydroxy-22-ene-vitamin D-3 is reduced during its metabolism: studies in chronic myeloid leukemia (RWLeu-4) cells and rat kidney, J STEROID B, 78(2), 2001, pp. 167-176
Citations number
21
Categorie Soggetti
Biochemistry & Biophysics
Journal title
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
ISSN journal
09600760 → ACNP
Volume
78
Issue
2
Year of publication
2001
Pages
167 - 176
Database
ISI
SICI code
0960-0760(200108)78:2<167:DBITSC>2.0.ZU;2-2
Abstract
1 alpha ,25-Dihydroxyvitamin D-3 [1 alpha ,25(OH)(2)D-3] is mainly metaboli zed via the C-24 oxidation pathway and undergoes several side chain modific ations which include C-24 hydroxylation, C-24 ketonization, C-23 hydroxylat ion and side chain cleavage between C-23 and C-24 to form the final product , calcitroic acid. In a recent study we reported that 1 alpha ,25-dihydroxy vitamin D-2 [1 alpha ,25(OH)(2)D-2] like 1 alpha ,25(OH)(2)D-3, is also con verted into the same final product, calcitroic acid. This finding indicated that 1 alpha ,25(OH)(2)D-2 also undergoes side chain cleavage between C-23 and C-24. As the side chain of 1 alpha ,25(OH)(2)D-2. when compared to the side chain of 1 alpha ,25(OH)(2)D-3, has a double bond between C-22 and C- 23 and an extra methyl group at C-24 position, it opens the possibility for both (a) double bond reduction and (b) demethylation to occur during the m etabolism of 1 alpha ,25(OH)(2)D-2. We undertook the present study to estab lish firmly the possibility of double bond reduction in the metabolism of v itamin D-2 related compounds. We compared the metabolism of 1 alpha ,25-dih ydroxy-22-ene-vitamin D-3 [1 alpha ,25(OH)(2)-22-ene-D-3], a synthetic vita min D analog whose side chain differs from that of lot,25(OH)2D3 only throu gh a sing-le modification namely the presence of a double bond between C-22 and C-23. Metabolism studies were performed in the chronic myeloid leukemi c cell line (RWLeu-4) and in the isolated perfused rat kidney. Our results indicate that both 1 alpha ,25(OH)(2)-22-ene-D-3 and 1 alpha ,25(OH)(2)D-3 are converted into common metabolites namely, 1 alpha ,24(R),25-trihydroxyv itamin D-3 [1 alpha ,24(R),25(OH)(3)D-3], 1 alpha ,25-dihydroxy-24-oxovitam in D-3 [1 alpha ,25(OH)(2)-24-oxo-D-3], 1 alpha ,23(S),25-trihydroxy-24-oxo vitamin D-3 and 1 alpha ,23-dihydroxy-24,25,26,27-tetranorvitamin D-3. This finding indicates that the double bond in the side chain of 1 alpha ,25(OH )(2)-22-ene-D-3 is reduced during its metabolism. Along with the aforementi oned metabolites, 1 alpha ,25(OH)(2)-22-ene-D-3 is also converted into two additional metabolites namely, 1 alpha ,24,25(OH)(3)-22-ene-D-3 and 1 alpha ,25(OH)(2)-24-oxo-22-ene-D-3. Furthermore, we did not observe direct conve rsion of 1 alpha ,25(OH)(2)-22-ene-D-3 into 1 alpha ,25(OH)(2)D-3. These fi ndings indicate that 1 alpha ,25(OH)(2)-22-ene-D-3 is first converted into 1 alpha ,24,25(OH)(3)-22-ene-D-3 and 1 alpha ,25(OH)(2)-24-oxo-22-ene-D-3. Then the double bonds in the side chains of 1 alpha ,24,25(OH)(3)-22-ene-D- 3 and 1 alpha ,25(OH)(2)-24-oxo-22-ene-D-3 undergo reduction to form 1 alph a ,24(R),25(OH)(3)D-3 and 1 alpha ,25(OH)(2)-24-oxo-D-3, respectively. Thus , our study indicates that the double bond in 1 alpha ,25(OH)(2)-22-ene-D-3 is reduced during its metabolism. Furthermore. it appears that the double bond reduction occurs only during the second or the third step of 1 alpha , 25(OH)(2)-22-ene-D-3 metabolism indicating that prior C-24 hydroxylation of 1 alpha ,25(OH)(2)- 22-ene-D-3 is required for the double bond reduction t o occur. (C) 2001 Elsevier Science Ltd. All rights reserved.